UA74567C2 - Кристалічні солі 7-[4-(4-фторфеніл)-6-ізопропіл-2-[метил(метилсульфоніл)аміно]піримідин-5-іл]-(3r,5s)-3,5-дигідроксигепт-6-енової кислоти - Google Patents
Кристалічні солі 7-[4-(4-фторфеніл)-6-ізопропіл-2-[метил(метилсульфоніл)аміно]піримідин-5-іл]-(3r,5s)-3,5-дигідроксигепт-6-енової кислоти Download PDFInfo
- Publication number
- UA74567C2 UA74567C2 UA2002097448A UA2002097448A UA74567C2 UA 74567 C2 UA74567 C2 UA 74567C2 UA 2002097448 A UA2002097448 A UA 2002097448A UA 2002097448 A UA2002097448 A UA 2002097448A UA 74567 C2 UA74567 C2 UA 74567C2
- Authority
- UA
- Ukraine
- Prior art keywords
- crystalline
- fluorophenyl
- amino
- dihydroxyhept
- salt
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 57
- BPRHUIZQVSMCRT-IAGOWNOFSA-N (3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-yl-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid Chemical class CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1C=C[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-IAGOWNOFSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 66
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 44
- 239000000243 solution Substances 0.000 claims description 44
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 25
- 238000002441 X-ray diffraction Methods 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 18
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 14
- 159000000007 calcium salts Chemical class 0.000 claims description 12
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 claims description 7
- -1 methyl(methylsulfonyl)amino Chemical group 0.000 claims description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 claims description 6
- DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical compound OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 claims description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical class CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 5
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 229910003002 lithium salt Inorganic materials 0.000 claims description 3
- 159000000002 lithium salts Chemical class 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000001914 filtration Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 102000004316 Oxidoreductases Human genes 0.000 description 7
- 108090000854 Oxidoreductases Proteins 0.000 description 7
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- YURNCBVQZBJDAJ-UHFFFAOYSA-N 2-heptenoic acid Chemical compound CCCCC=CC(O)=O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RWZYEKXHAQMRIO-UHFFFAOYSA-N 2,2-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C(O)(O)CCCC=C RWZYEKXHAQMRIO-UHFFFAOYSA-N 0.000 description 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 244000275904 brauner Senf Species 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- JCRCPEDXAHDCAJ-UHFFFAOYSA-N ethoxy(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(OCC)C1=CC=CC=C1 JCRCPEDXAHDCAJ-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- RMYXELUYVYVDAI-UHFFFAOYSA-N methyl 2-amino-4-(4-fluorophenyl)-6-propan-2-ylpyrimidine-5-carboxylate Chemical compound COC(=O)C1=C(C(C)C)N=C(N)N=C1C1=CC=C(F)C=C1 RMYXELUYVYVDAI-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910021421 monocrystalline silicon Inorganic materials 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0003305.0A GB0003305D0 (en) | 2000-02-15 | 2000-02-15 | Pyrimidine derivatives |
| PCT/GB2001/000574 WO2001060804A1 (en) | 2000-02-15 | 2001-02-12 | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA74567C2 true UA74567C2 (uk) | 2006-01-16 |
Family
ID=9885517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002097448A UA74567C2 (uk) | 2000-02-15 | 2001-12-02 | Кристалічні солі 7-[4-(4-фторфеніл)-6-ізопропіл-2-[метил(метилсульфоніл)аміно]піримідин-5-іл]-(3r,5s)-3,5-дигідроксигепт-6-енової кислоти |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US6841554B2 (cs) |
| EP (2) | EP1263739B9 (cs) |
| JP (1) | JP4099333B2 (cs) |
| KR (1) | KR100708262B1 (cs) |
| CN (1) | CN1210266C (cs) |
| AR (1) | AR029228A1 (cs) |
| AT (2) | ATE449079T1 (cs) |
| AU (1) | AU775569B2 (cs) |
| BG (1) | BG65562B1 (cs) |
| BR (1) | BR0108378A (cs) |
| CA (1) | CA2397450C (cs) |
| CO (1) | CO5280213A1 (cs) |
| CY (2) | CY1107225T1 (cs) |
| CZ (1) | CZ302136B6 (cs) |
| DE (2) | DE60132178T2 (cs) |
| DK (2) | DK1263739T3 (cs) |
| EE (1) | EE05288B1 (cs) |
| ES (2) | ES2298214T3 (cs) |
| GB (1) | GB0003305D0 (cs) |
| HU (1) | HU228422B1 (cs) |
| IL (2) | IL150807A0 (cs) |
| IS (1) | IS2592B (cs) |
| MX (1) | MXPA02007819A (cs) |
| MY (1) | MY129018A (cs) |
| NO (1) | NO323770B1 (cs) |
| NZ (1) | NZ520032A (cs) |
| PL (1) | PL206729B1 (cs) |
| PT (2) | PT1263739E (cs) |
| RU (1) | RU2265599C2 (cs) |
| SA (1) | SA01220166B1 (cs) |
| SI (2) | SI1263739T1 (cs) |
| SK (1) | SK287144B6 (cs) |
| UA (1) | UA74567C2 (cs) |
| WO (1) | WO2001060804A1 (cs) |
| ZA (1) | ZA200205331B (cs) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| AU2002318041B2 (en) | 2001-07-13 | 2008-01-03 | Astrazeneca Uk Limited | Preparation of aminopyrimidine compounds |
| US20050222415A1 (en) * | 2002-05-21 | 2005-10-06 | Yatendra Kumar | Process for the preparation of rosuvastatin |
| JP2005532362A (ja) * | 2002-06-13 | 2005-10-27 | ノバルティス アクチエンゲゼルシャフト | インドール誘導スタチンのカルシウム塩 |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| NZ540722A (en) | 2002-12-16 | 2008-03-28 | Astrazeneca Uk Ltd | Process for the preparation of pyrimidine compounds and intermediates thereof |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| AU2003269478A1 (en) * | 2003-08-27 | 2005-03-16 | Hetero Drugs Limited | A novel process for amorphous rosuvastatin calcium |
| EP1562912A2 (en) | 2003-08-28 | 2005-08-17 | Teva Pharmaceutical Industries Limited | Process for preparation of rosuvastatin calcium |
| UY28501A1 (es) * | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| GB0321827D0 (en) * | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| CN1886383A (zh) * | 2003-10-22 | 2006-12-27 | 兰贝克赛实验室有限公司 | 无定形罗苏伐他汀钙的制备方法 |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| EP1601658A1 (en) * | 2003-11-24 | 2005-12-07 | Teva Pharmaceutical Industries Limited | Crystalline ammonium salts of rosuvastatin |
| WO2005077916A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
| JP4733047B2 (ja) | 2003-12-02 | 2011-07-27 | テバ ファーマシューティカル インダストリーズ リミティド | ロスバスタチンの特性評価のためのリファレンス・スタンダード |
| WO2005077917A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Amorphous salts of rosuvastatin |
| US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
| GB0406757D0 (en) * | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
| EP1673351A1 (en) | 2004-07-13 | 2006-06-28 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
| EP1797046A2 (en) * | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
| GB0428328D0 (en) | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
| JP4713574B2 (ja) | 2005-02-22 | 2011-06-29 | テバ ファーマシューティカル インダストリーズ リミティド | ロスバスタチンアルキルエーテルを含まないロスバスタチンおよびその塩およびそれらを製造する方法 |
| CA2499047A1 (en) * | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
| EP2508514B1 (en) | 2005-06-24 | 2017-10-18 | LEK Pharmaceuticals d.d. | Process for preparing amorphous rosuvastatin calcium free of impurities |
| HUE027012T2 (en) * | 2005-06-24 | 2016-10-28 | Lek Pharmaceuticals | Method for producing pure amorphous rosuvastatin calcium |
| CA2619576C (en) | 2005-08-16 | 2011-12-06 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| ES2564250T3 (es) | 2006-05-03 | 2016-03-21 | Msn Laboratories Private Limited | Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas |
| WO2008036286A1 (en) * | 2006-09-18 | 2008-03-27 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin calcium |
| WO2008038132A1 (en) * | 2006-09-28 | 2008-04-03 | Aurobindo Pharma Limited | Crystalline diamine salts of rosuvastatin |
| EP2086945B1 (en) * | 2006-10-09 | 2016-01-06 | MSN Laboratories Private Limited | Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| EP2086946A2 (en) * | 2006-11-29 | 2009-08-12 | Dr. Reddy's Laboratories Ltd. | Rosuvastatin dehydroabietylamine salt |
| HU230981B1 (hu) * | 2007-10-12 | 2019-08-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin só előállítására |
| CA2725052C (en) | 2008-05-27 | 2014-09-16 | Changzhou Pharmaceutical Factory Co., Ltd. | Preparation method of rosuvastatin calcium and its intermediates |
| WO2010035284A2 (en) * | 2008-09-26 | 2010-04-01 | Matrix Laboratories Ltd | An improved process for the preparation of rosuvastatin calcium |
| PL2387566T3 (pl) * | 2009-01-14 | 2014-10-31 | Krka Tovarna Zdravil D D Novo Mesto | Sposób przygotowania rosuwastatyny |
| CA2749727A1 (en) | 2009-01-15 | 2010-07-22 | Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag | Process for the preparation of rosuvastatin salts |
| WO2010089770A2 (en) | 2009-01-19 | 2010-08-12 | Msn Laboratories Limited | Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof |
| HUP0900285A2 (en) | 2009-05-07 | 2011-01-28 | Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag | Rosuvastatin salts and preparation thereof |
| EP2526099B1 (en) | 2010-01-18 | 2016-03-30 | MSN Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| CN101935304B (zh) * | 2010-06-22 | 2012-04-18 | 重庆博腾制药科技股份有限公司 | 瑞舒伐他汀甘氨酸叔丁酯盐及其制备方法 |
| WO2012063115A2 (en) | 2010-11-11 | 2012-05-18 | Jubilant Life Sciences Ltd. | Process for the preparation of rosuvastatin calcium via novel amine intermediate |
| HU230737B1 (hu) | 2010-11-16 | 2018-01-29 | EGIS Gyógyszergyár Nyrt | Eljárás rosuvastatin só előállítására |
| HU229260B1 (en) | 2010-11-29 | 2013-10-28 | Egis Gyogyszergyar Nyrt | Process for preparation of rosuvastatin salts |
| WO2012073256A1 (en) * | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
| HU230987B1 (hu) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
| WO2012176218A1 (en) * | 2011-06-24 | 2012-12-27 | Ind-Swift Laboratories Limited | Process for preparing rosuvastatin calcium through novel amine salt |
| EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
| JP6596339B2 (ja) | 2014-02-06 | 2019-10-23 | 株式会社エーピーアイ コーポレーション | ロスバスタチンカルシウム及びその中間体の製造方法 |
| CN106397335A (zh) * | 2016-08-31 | 2017-02-15 | 湖北祥云(集团)化工股份有限公司 | 瑞舒伐他汀中间体的制备方法 |
| USD841087S1 (en) | 2016-11-17 | 2019-02-19 | Ccl Label, Inc. | Label sheet with a feed edge assembly |
| CN109651259B (zh) * | 2018-12-29 | 2020-05-19 | 浙江永太科技股份有限公司 | 一种瑞舒伐他汀钙关键中间体的纯化方法 |
| CN110642790B (zh) * | 2019-10-21 | 2021-02-23 | 山东理工职业学院 | 瑞舒伐他汀钙及其中间体的制备方法 |
| CN115417824A (zh) * | 2022-09-21 | 2022-12-02 | 安徽美诺华药物化学有限公司 | 一种瑞舒伐他汀中间体的高纯度制备方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4319039A (en) | 1979-06-15 | 1982-03-09 | Merck & Co., Inc. | Preparation of ammonium salt of hypocholesteremic fermentation product |
| EP0026044B1 (en) | 1979-08-24 | 1983-06-08 | Beecham Group Plc | Amine salt of clavulanic acid, its preparation and use |
| US4294846A (en) | 1979-09-21 | 1981-10-13 | Merck & Co., Inc. | Hypocholesteremic fermentation products and products of preparation |
| JPS56142236A (en) | 1980-04-08 | 1981-11-06 | Sankyo Co Ltd | Ml-236a and mb-530a derivative |
| DE3170885D1 (en) * | 1980-11-03 | 1985-07-11 | Monsanto Co | Tough thermoplastic nylon compositions and processes for preparing them |
| JPS57185275A (en) | 1981-05-07 | 1982-11-15 | Sankyo Co Ltd | Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives |
| US4668699A (en) | 1985-08-05 | 1987-05-26 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US4940727A (en) | 1986-06-23 | 1990-07-10 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
| US4997848A (en) | 1987-10-27 | 1991-03-05 | Sankyo Company, Limited | Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition |
| US4868185A (en) | 1987-12-10 | 1989-09-19 | Warner-Lambert Company | 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
| NZ227743A (en) | 1988-01-27 | 1991-01-29 | May & Baker Ltd | Isoquinolinone derivatives and their pharmaceutical compositions |
| EP0326388A3 (en) | 1988-01-29 | 1990-11-28 | Johnson Matthey, Inc., | Waste heat recovery having combined co and nox removal apparatus and method |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5089523A (en) | 1990-05-11 | 1992-02-18 | E. R. Squibb & Sons, Inc. | Fluorinated derivatives of mevinic acids |
| CA2043525A1 (en) | 1990-06-24 | 1991-12-25 | Donald S. Karanewsky | Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method |
| US5223415A (en) | 1990-10-15 | 1993-06-29 | Merck & Co., Inc. | Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid) |
| GB9027018D0 (en) * | 1990-12-12 | 1991-01-30 | Ici Plc | Heterocyclic compounds |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| JP3528186B2 (ja) | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| SI9300296B (sl) | 1992-06-11 | 1998-06-30 | Smithkline Beecham P.L.C. | Postopek in intermedianti za pripravo klavulanske kisline |
| US5369123A (en) | 1992-10-09 | 1994-11-29 | E. R. Squibb & Sons, Inc. | Nitrogen-substituted mevinic acid derivatives useful as HMG-CoA reductase inhibitors |
| CA2137049A1 (en) | 1993-12-15 | 1995-06-16 | John K. Thottathil | Amino acid salts of and methods for preparing antihypercholesterolemic tetrazole compounds |
| US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
| SI9500134B (sl) | 1995-04-20 | 2004-04-30 | Lek, | Postopek za pripravo čistih alkalijskih soli klavulanske kisline |
| IL128862A (en) | 1995-07-17 | 2007-12-03 | Warner Lambert Co | [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate |
| AT403375B (de) | 1995-11-15 | 1998-01-26 | Biochemie Gmbh | Verfahren zur fällung von alkalisalzen der clavulansäure |
| SI20070A (sl) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
| GB9900339D0 (en) * | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| AR022462A1 (es) | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
| GB0000710D0 (en) | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
| GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| HK1046682B (zh) * | 1999-07-13 | 2005-04-08 | 隆萨股份公司 | 2-氨基-4-(4-氟苯基)-6-烷基嘧啶-5-羧酸酯的制备方法 |
| GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| US6814554B1 (en) * | 2003-06-04 | 2004-11-09 | Rechi Precision Co., Ltd. | Vortex compressor |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| GB0321827D0 (en) | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
-
2000
- 2000-02-15 GB GBGB0003305.0A patent/GB0003305D0/en not_active Ceased
-
2001
- 2001-02-12 PT PT01904167T patent/PT1263739E/pt unknown
- 2001-02-12 SI SI200130805T patent/SI1263739T1/sl unknown
- 2001-02-12 BR BR0108378-3A patent/BR0108378A/pt not_active Application Discontinuation
- 2001-02-12 DE DE60132178T patent/DE60132178T2/de not_active Expired - Lifetime
- 2001-02-12 IL IL15080701A patent/IL150807A0/xx active IP Right Grant
- 2001-02-12 EE EEP200200445A patent/EE05288B1/xx not_active IP Right Cessation
- 2001-02-12 MX MXPA02007819A patent/MXPA02007819A/es active IP Right Grant
- 2001-02-12 AU AU32084/01A patent/AU775569B2/en not_active Ceased
- 2001-02-12 JP JP2001560189A patent/JP4099333B2/ja not_active Expired - Lifetime
- 2001-02-12 NZ NZ520032A patent/NZ520032A/en not_active IP Right Cessation
- 2001-02-12 SK SK1174-2002A patent/SK287144B6/sk not_active IP Right Cessation
- 2001-02-12 WO PCT/GB2001/000574 patent/WO2001060804A1/en not_active Ceased
- 2001-02-12 RU RU2002124621/04A patent/RU2265599C2/ru not_active IP Right Cessation
- 2001-02-12 EP EP01904167A patent/EP1263739B9/en not_active Expired - Lifetime
- 2001-02-12 PT PT07118593T patent/PT1873148E/pt unknown
- 2001-02-12 US US10/203,890 patent/US6841554B2/en not_active Expired - Lifetime
- 2001-02-12 AT AT07118593T patent/ATE449079T1/de active
- 2001-02-12 DK DK01904167T patent/DK1263739T3/da active
- 2001-02-12 AT AT01904167T patent/ATE382610T1/de active
- 2001-02-12 CA CA002397450A patent/CA2397450C/en not_active Expired - Fee Related
- 2001-02-12 ES ES01904167T patent/ES2298214T3/es not_active Expired - Lifetime
- 2001-02-12 KR KR1020027010581A patent/KR100708262B1/ko not_active Expired - Fee Related
- 2001-02-12 ES ES07118593T patent/ES2335542T3/es not_active Expired - Lifetime
- 2001-02-12 EP EP07118593A patent/EP1873148B1/en not_active Expired - Lifetime
- 2001-02-12 DK DK07118593.8T patent/DK1873148T3/da active
- 2001-02-12 DE DE60140581T patent/DE60140581D1/de not_active Expired - Lifetime
- 2001-02-12 SI SI200130956T patent/SI1873148T1/sl unknown
- 2001-02-12 PL PL356472A patent/PL206729B1/pl unknown
- 2001-02-12 HU HU0204051A patent/HU228422B1/hu not_active IP Right Cessation
- 2001-02-12 CN CNB018050271A patent/CN1210266C/zh not_active Expired - Lifetime
- 2001-02-12 CZ CZ20022754A patent/CZ302136B6/cs not_active IP Right Cessation
- 2001-02-13 MY MYPI20010646A patent/MY129018A/en unknown
- 2001-02-14 CO CO01011529A patent/CO5280213A1/es not_active Application Discontinuation
- 2001-02-15 AR ARP010100696A patent/AR029228A1/es unknown
- 2001-06-23 SA SA01220166A patent/SA01220166B1/ar unknown
- 2001-12-02 UA UA2002097448A patent/UA74567C2/uk unknown
-
2002
- 2002-07-03 ZA ZA200205331A patent/ZA200205331B/xx unknown
- 2002-07-18 IL IL150807A patent/IL150807A/en not_active IP Right Cessation
- 2002-07-31 BG BG106969A patent/BG65562B1/bg unknown
- 2002-08-09 IS IS6494A patent/IS2592B/is unknown
- 2002-08-14 NO NO20023853A patent/NO323770B1/no not_active IP Right Cessation
-
2004
- 2004-11-10 US US10/985,019 patent/US7129352B2/en not_active Expired - Lifetime
-
2008
- 2008-03-03 CY CY20081100245T patent/CY1107225T1/el unknown
-
2010
- 2010-01-25 CY CY20101100075T patent/CY1109756T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA74567C2 (uk) | Кристалічні солі 7-[4-(4-фторфеніл)-6-ізопропіл-2-[метил(метилсульфоніл)аміно]піримідин-5-іл]-(3r,5s)-3,5-дигідроксигепт-6-енової кислоти | |
| CA2356212C (en) | Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt | |
| ZA200602263B (en) | Polymorphic forms of a known antihyperlipemic agent | |
| HK1051532B (en) | Crystalline salts of 7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | |
| KR20070017970A (ko) | 공지된 항고지혈증제의 다형성 형태 | |
| MXPA06003052A (en) | Polymorphic forms of a known antihyperlipemic agent |